Isabelle Chemin is currently Research Director at INSERM U1052 at the Center for Research on Cancer of Lyon. Dr. Chemin was born in France and studied in Lyon I University (PhD at Inserm U271). Dr. Chemin worked on projects concerning hepatitis B natural history and animal models. She spent several years at IARC on HBV–AFB1 interaction and in the University of Freiburg (Germany) on new anti-HBV therapies. Since several years she focused on HBV variants and Hepatocellularcarcinoma, including prognostic and predictive markers for HCC development. She has been instrumental in the implementation and development of several collaborative studies (industry/Academia), including with South America, North and West Africa. Dr. Chemin has published in the areas of hepatitis induced by HBV, HCV or of unknown etiology. Active collaboration is ongoing with IARC (Lyon, F), Imperial college (London, UK) on the development of HCC through in vitro and field studies. She published more than 100 reviewed papers and reviews. Her current interests include HBV and HDV variants, HCC and development of improvement of therapeutic approaches of chronic hepatitis and HCC.